Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 10% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson

3Q Revenues: $17.6 billion (+3%)
 
3Q Earnings: $3.0 billion (flat)
 
YTD Revenues: $53.0 billion (+1%)
 
YTD Earnings: $10.3 billion (+25%)
 
Comments: Pharmaceutical sales were $7.0 billion in the quarter, up 10%. Domestic sales were up 8%. International sales increased 12%. Growth was driven by Invega Sustenna/Xeplion ($324 million, +53%), Remicade ($1.7 billion, +6%), Simponi ($266 million, +44%), Stelara ($370 million, +29%), Velcade ($404 million, +24%), and Prezista ($410 million, +13%), as well as strong sales of new products Zytiga ($464 million, +75%), and Xarelto ($246 million, +68%). R&D expenses were up 6% to $2.0 billion in the quarter. Consumer sales were $3.6 billion, up 2% in the quarter, and Medical Devices & Diagnostics sales down 2% to were $6.9 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters